Join us in Gothernburg, Sweden for the second ELRIG meeting on Therapeutic Oligonucleotides - Drugging the Undruggables. Learn more about our involvement in the event below.
Evotec At ELRIG
Saman Honarnejad is an acting conference co-director. Hilary Brooks will chair Track 2: Safety and Efficacy Advancements. Learn more about the track below.
Safety and Efficacy Advancements
Track 2, Safety and Efficacy Advancements, will explore advancements in oligonucleotide safety and efficacy over the years including how a basic understanding of RNA interference mechanisms, novel chemistries, immune activation and off-target activity can influence oligonucleotide design and discovery and how this knowledge can influence progress in workflows for oligonucleotide drug discovery
Track Chair: Hilary Brooks, VP Oligonucleotide Tx, Scientific Director
